News

AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer…
Read More...

Merck, known as MSD outside the United States and Canada, and VelosBio Inc. announced that the companies have entered into a definitive agreement pursuant to which Merck, through a…
Read More...

AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in…
Read More...

TFF Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF)…
Read More...

Taysha Gene Therapies Inc. a patient-centric gene therapy company focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of…
Read More...

Isotopia Molecular Imaging is pleased to announce that it has begun a collaboration with Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company, for the supply of…
Read More...

NanOlogy LLC, a clinical-stage oncology company advancing intratumoral therapy for solid tumors, has enrolled the first patient in a Phase 2 clinical trial of NanoPac (sterile…
Read More...

Axsome Therapeutics, Inc. and Veeva Systems announced a strategic partnership to augment the build of Axsome’s Digital-Centric Commercialization (DCC™) platform. Veeva is the leader in…
Read More...

XNK Therapeutics AB ("XNK") announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its leading investigational drug candidate in…
Read More...

Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2…
Read More...

Ionis Pharmaceuticals, Inc. and its wholly owned subsidiary Akcea Therapeutics, Inc., announced that Pfizer Inc. has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in…
Read More...

GW Pharmaceuticals plc announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity. Nabiximols,…
Read More...

ACG, a leading supplier of integrated pharmaceutical manufacturing solutions announced acquisition of a significant stake in Mumbai-based start-up IQGEN-X. IQGEN-X is a Contract…
Read More...

PerkinElmer, Inc. and Horizon Discovery Group plc are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will…
Read More...

Roche announced that the European Commission has approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of adult patients with advanced or…
Read More...

Zucara Therapeutics Inc. a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), announced that…
Read More...

TFF Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling breakthroughs in medicine through immune profiling,…
Read More...

Telix Pharmaceuticals Limited announces it has entered into a strategic licence and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited (‘China Grand…
Read More...

Biogen and Eisai, Co., Ltd. announced that the European Medicines Agency (EMA) has confirmed it has accepted for review, following a standard timetable, the Marketing Authorization…
Read More...

Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based medicines for the treatment of life-threatening…
Read More...